KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non-Current Deferred Tax Liability: 2015-2024

Historic Non-Current Deferred Tax Liability for Supernus Pharmaceuticals (SUPN) over the last 7 years, with Dec 2024 value amounting to $5.0 million.

  • Supernus Pharmaceuticals' Non-Current Deferred Tax Liability fell 94.97% to $981,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $981,000, marking a year-over-year decrease of 94.97%. This contributed to the annual value of $5.0 million for FY2024, which is 96.83% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Non-Current Deferred Tax Liability of $5.0 million as of FY2024, which was down 96.83% from $156.3 million recorded in FY2023.
  • Supernus Pharmaceuticals' 5-year Non-Current Deferred Tax Liability high stood at $229.6 million for FY2021, and its period low was $5.0 million during FY2024.
  • In the last 3 years, Supernus Pharmaceuticals' Non-Current Deferred Tax Liability had a median value of $156.3 million in 2023 and averaged $115.3 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Non-Current Deferred Tax Liability surged by 216.61% in 2020, and later crashed by 96.83% in 2024.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Non-Current Deferred Tax Liability stood at $118.1 million in 2020, then soared by 94.50% to $229.6 million in 2021, then fell by 19.58% to $184.7 million in 2022, then declined by 15.39% to $156.3 million in 2023, then slumped by 96.83% to $5.0 million in 2024.